Everand Logo

Welcome to Everand!

  • Discover this podcast and so much more

    Podcasts are free to enjoy without a subscription. We also offer ebooks, audiobooks, and so much more for just $11.99/month.

    Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer

    Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer

    FromThe Lancet Oncology in conversation with

    Start listeningView podcast show

    Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer

    FromThe Lancet Oncology in conversation with

    ratings:
    Length:
    10 minutes
    Released:
    Jun 30, 2018
    Format:
    Podcast episode

    Description

    Bo Jan Noordman joins The Lancet Oncology to discuss the findings from his study of residual disease detection in oesophageal cancer.Continue this conversation on social!Follow us today at...https://twitter.com/thelancet & https://Twitter.com/TheLancetOncolhttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv
    Released:
    Jun 30, 2018
    Format:
    Podcast episode

    Titles in the series (100)

    Editors of The Lancet Oncology and the journal’s authors explore their research and its impact on people’s health, health care, and health policy in this regular podcast.